We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Beckman Coulter Integrates BioRAPTR™ for High-Throughput Assay Miniaturization

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Beckman Coulter, Inc. demonstrates its BioRAPTR FRD™ microfluidic workstation at LabAutomation2007. The system is shown in two configurations – standalone and integrated with Beckman Coulter’s PARADIGM™ Detection Platform, Biomek® NXp liquid handler and BRT Robotic Transport.

According to Company, ideal for assay miniaturization applications in drug discovery, genomics and proteomics, the BioRAPTR non-contact, high-precision dispenser can deliver increased capacity. With the BioRAPTR’s design, the plate moves while the pipetting head is stationary, creating a shorter fluid path, for high precision with low dead volume.

Flexible programming is done through an Excel* spreadsheet and can allow a variety of reagents to be dispensed into any well at a range of volumes. The BioRAPTR has been validated with biological samples, demonstrating high cell viability.

Integration of the BioRAPTR with Beckman Coulter’s Biomek and PARADIGM systems enables high-throughput applications such as compound screening.

The company has also recently introduced a companion workstation, the PicoRAPTR™, a multimode workstation that features both piezo and syringe dispensing for low-volume aspirate and dispenses operations involved in dose response curve generation and compound reformatting activities.

“This is the first time we have shown the BioRAPTR, developed by Aurora Discovery, as a Beckman Coulter product integrated with our other systems,” commented Noreen Galvin, Ph.D., director of automated solutions for Beckman Coulter.

“We are currently working on additional integrations for high-throughput compound screening applications.  The combination of high-quality, high-content data and reduced costs is driving rapid acceptance of this technology at pharmaceutical companies.”